Results for koagulacijske translation from Slovenian to English

koagulacijske lastnosti
coagulation properties

vplivi na koagulacijske teste
interference with assay for coagulation tests

barvo krvi, koagulacijske lastnosti krvi in prisotnost tujkov v krvi;
the colour of the blood, its coagulation properties and the possible presence of foreign bodies in the blood;

barvo krvi, njene koagulacijske lastnosti in morebitno prisotnost tujkov v krvi;
the colour of the blood, its coagulation properties and the possible presence of foreign bodies in the blood;

za epizode krvavitev ni bilo vzorca in med skupinami ni bilo razlik glede na koagulacijske parametre.
there was no pattern for the bleeding events and no difference between treatment groups in coagulation parameters.

fibrinogen je koncentrat koagulacijske beljakovine, trombin pa je encim, ki povzroči strjevanje koagulacijske beljakovine.
fibrinogen is a concentrate of clottable protein and thrombin is an enzyme that causes clottable protein to coalesce.

glavna sestavina humane koagulacijske beljakovine je fibrinogen, beljakovina, ki sodeluje pri naravnem procesu strjevanja krvi.
the human clottable protein contains as its main component, fibrinogen, a protein involved in the natural clotting process.

to vpliva na vse od trombina odvisne koagulacijske teste; vrednosti aptt se npr. povečajo sorazmerno z odmerkom.
as a result all thrombin dependent coagulation assays are affected, e.g. the aptt values increase in a dose-dependent fashion.

klinične informacije o kombinaciji varfarina in tolkapona so omejene, zato je treba ob sočasnem dajanju teh dveh zdravil spremljati koagulacijske parametre.
since clinical information is limited regarding the combination of warfarin and tolcapone, coagulation parameters should be monitored when these drugs are co-administered.

1 viala vsebuje 2 ml humane koagulacijske beljakovine (50 – 90 mg/ ml) raztopina 2:
1 vial containing 2 ml of human clottable protein (50 – 90 mg/ ml) component 2:

varfarin: klinične informacije o kombinaciji varfarina in tolkapona so omejene, zato je treba ob sočasnem dajanju teh dveh zdravil spremljati koagulacijske parametre.
since clinical information is limited regarding the combination of warfarin and tolcapone, coagulation parameters should be monitored when these drugs are co-administered.

pred uvedbo zdravljenja s tigeciklinom in redno med zdravljenjem je treba spremljati izvide testov jetrne funkcije, koagulacijske parametre, hematološke parametre, amilazo in lipazo.
liver function tests, coagulation parameters, haematology parameters, amylase and lipase should be monitored prior to treatment initiation with tigecycline and regularly while on treatment.

v odmerkih, ki se uporabljajo pri zdravljenju, fondaparinuks ne vpliva, v klinično pomembnem obsegu, na rutinske koagulacijske teste v plazmi, kot so merjenje aktiviranega parcialnega
fondaparinux does not inactivate thrombin (activated factor ii) and has no effects on platelets. lo at the doses used for treatment, fondaparinux does not, to a clinically relevant extent, affect routine coagulation tests such as activated partial thromboplastin time (aptt), activated clotting time (act) no

pri bolnikih, ki se sočasno zdravijo s peroralnimi antikoagulanti, je treba spremljati koagulacijske parametre (glejte poglavji 4.5 in 4.8).
coagulation parameters should be monitored in patients treated with concomitant oral anticoagulants (see section 4.5 and 4.8).

vsa zdravila, izdelana iz sestavin krvi, ki jih industrijsko izdelujejo javne ali zasebne ustanove, kot npr. zdravila, ki vključujejo zlasti albumin, koagulacijske faktorje in imunoglobuline človeškega izvora.
medicinal products based on blood constitutents which are prepared industrially by public or private establishments, such medicinal products including, in particular, albumin, coagulating factors and immunoglobulins of human origin.

edoksaban podaljšuje standardne koagulacijske teste, na primer protrombinski čas (pt), inr in aktivirani delni tromboplastinski čas (aptt) zaradi inhibicije fxa.
edoxaban prolongs standard clotting tests such as prothrombin time (pt), inr, and activated partial thromboplastin time (aptt) as a result of fxa inhibition.

v začetnem obdobju po presaditvi je treba rutinsko nadzirati naslednje parametre: krvni tlak, ekg, nevrološko stanje in stanje vida, koncentracijo glukoze na tešče, elektrolite (zlasti kalij), teste delovanja jeter in ledvic, hematološke parametre, koagulacijske vrednosti in koncentracijo beljakovin v plazmi.
during the initial post-transplant period, monitoring of the following parameters should be undertaken on a routine basis: blood pressure, ecg, neurological and visual status, fasting blood glucose levels, electrolytes (particularly potassium), liver and renal function tests, haematology parameters, coagulation values, and plasma protein determinations.